Casey Markland, MD
Family Medicine · Moore, OKNPI 1568504033
Payments from drug & device makers
Across 367 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$834
- Lilly USA, LLC$760
- Pfizer$544
- AstraZeneca$392
- GSK$381
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,25498%
- Education$1482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,313 |
| Novo Nordisk | 60 | $834 |
| Lilly USA, LLC | 45 | $760 |
| Pfizer | 32 | $544 |
| AstraZeneca | 19 | $392 |
| GSK | 27 | $381 |
| Boehringer Ingelheim | 20 | $362 |
| Amgen | 18 | $301 |
| Bayer | 8 | $207 |
| Abbott | 10 | $184 |
| Astellas Pharma US Inc | 7 | $126 |
| Biohaven Pharmaceuticals, Inc. | 7 | $121 |
| Exact Sciences | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $84 |
| Merck | 6 | $77 |
| Nevro Corp. | 2 | $71 |
| Johnson & Johnson | 4 | $68 |
| Dexcom, Inc. | 3 | $52 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$6,402 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 96 | $123,033 |
| OzempicSemaglutide | 88 | $90,159 |
| JardianceEmpagliflozin | 41 | $52,985 |
| EliquisApixaban | 63 | $42,435 |
| FarxigaDapagliflozin Propanediol | 33 | $41,146 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,629 |
| TrulicityDulaglutide | 11 | $24,105 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $16,202 |
| MyrbetriqMirabegron | 11 | $14,242 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $13,112 |
| LinzessLinaclotide | 15 | $10,763 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,158 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,612 |
| TrulancePlecanatide | 12 | $7,451 |
| Dexlansoprazole DrDexlansoprazole | 15 | $5,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $760 | $147,139107 claims |
| Novo NordiskOzempic | $834 | $90,15988 claims |
| Boehringer IngelheimJardiance | $362 | $52,98541 claims |
| PfizerEliquis | $544 | $42,43563 claims |
| AstraZenecaFarxiga | $392 | $41,14633 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $381 | $30,98940 claims |
| Astellas Pharma US IncMyrbetriq | $126 | $14,24211 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $43 | $13,11216 claims |
| AbbVieLinzess | $1,313 | $10,76315 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $84 | $7,45112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Moore
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.